American Express Co vs Ginkgo Bioworks Holdings Inc — how do they compare? American Express Co trades at $358.39 (market cap $242.27B), while Ginkgo Bioworks Holdings Inc trades at $8.98 (market cap $590.53M). The key difference: American Express Co is far larger — about 410.3× Ginkgo Bioworks Holdings Inc's market cap, and American Express Co pays a 1.07% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals.
| AXP | DNA | |
|---|---|---|
Market Cap | $242.27B | $590.53M |
Sector | Financials | Health |
52-Week High | $384.82 | $16.14 |
52-Week Low | $292.27 | $5.48 |
Dividend Yield | 1.07% | — |
Enterprise Value | — | $627.78M |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
DNA trades at $9.05, down 0.44% on the day, reflecting ongoing investor caution. The technical outlook is bearish, while fundamentals show significant losses with a net income margin of -201.05% and negative cash flows. Recent earnings have been mixed, missing estimates in two of the last three quarters. Analyst sentiment is divided, with a slight lean toward buy ratings amid high volatility and operational challenges.
The outlook remains challenging due to persistent losses and cash burn, though analyst coverage suggests potential long-term value. Key risks include execution missteps and intense competition in biotechnology. Investment appeal hinges on future profitability improvements and successful business model execution.
Trailing returns across standard periods
Latest headlines on both assets
American Express Company is a global payment and travel company. The Company's principal products and services are charge and credit payment card products and travel-related services offered to consumers and businesses around the world.
Read more on AXP →Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →